Here you can find the archive of all 新闻稿 prior to 2021
Filter by date:
Showing 973 press releases before 2021
-
Forxiga recommended for approval in the EU by CHMP for heart failure
-
Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD
-
COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials
-
COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, 巴西, South Africa and India
-
Farxiga granted Breakthrough Therapy Designation in US for chronic kidney disease
-
Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer
-
Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
-
Lynparza reduced the risk of death by 31% in BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in PROfound Phase III trial
-
Tagrisso reduced the risk of disease recurrence in the brain by 82% in the adjuvant treatment of early-stage EGFR-mutated lung cancer
-
Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo
Latest articles and press releases
All of our latest press releases and articles are available to explore
